Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats
- PMID: 2419508
- DOI: 10.1111/j.1471-4159.1986.tb00650.x
Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats
Abstract
A dialysis cannula was implanted into rat striatum while the animals were anesthetized, and the area was perfused with Ringer solution while the animals were unanesthetized after at least 3 days following surgery. Concentrations of the metabolites of 3,4-dihydroxyphenylethylamine (DA) and 5-hydroxytryptamine (5-HT) in the perfusate were determined by HPLC with electrochemical detection. Levels of the DA metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the perfusate significantly decreased after pargyline administration (50 mg/kg i.p.), which may inhibit not only monoamine oxidase (MAO)-B but also MAO-A in these high doses. The level of the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA) also decreased after pargyline treatment, although change in the relative level of 5-HIAA was less than that of DOPAC or HVA. To clarify the mechanisms for the metabolism of monoamines in rat striatum, highly specific MAO-A and -B inhibitors were used in the following experiments. Treatment with l-deprenyl (10 mg/kg), a specific inhibitor for MAO-B, did not cause any statistically significant change in DOPAC, HVA, and 5-HIAA levels. No significant change was found in rat striatal homogenates at 2 h after the same treatment with l-deprenyl. In contrast, low-dose treatment (1 mg/kg) with clorgyline, a specific inhibitor for MAO-A, caused a significant decrease in levels of these three metabolites in both the perfusates and tissue homogenates. In addition to the above three metabolites, the level of 3-methoxytyramine, which is an indicator of the amount of DA released, greatly increased after treatment with a low dose (1 mg/kg) of clorgyline.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.J Neurochem. 1996 Oct;67(4):1532-9. doi: 10.1046/j.1471-4159.1996.67041532.x. J Neurochem. 1996. PMID: 8858937
-
Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.Br J Pharmacol. 2000 Aug;130(8):1992-8. doi: 10.1038/sj.bjp.0703493. Br J Pharmacol. 2000. PMID: 10952692 Free PMC article.
-
In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.J Neural Transm Park Dis Dement Sect. 1995;10(2-3):79-89. doi: 10.1007/BF02251224. J Neural Transm Park Dis Dement Sect. 1995. PMID: 9620056
-
Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties).Pharmacol Toxicol. 2001 Nov;89(5):217-24. doi: 10.1034/j.1600-0773.2001.d01-151.x. Pharmacol Toxicol. 2001. PMID: 11881974 Review.
-
The High-Precision Liquid Chromatography with Electrochemical Detection (HPLC-ECD) for Monoamines Neurotransmitters and Their Metabolites: A Review.Molecules. 2024 Jan 19;29(2):496. doi: 10.3390/molecules29020496. Molecules. 2024. PMID: 38276574 Free PMC article. Review.
Cited by
-
Electrophysiological effects of monoamine oxidase inhibition on rat midbrain dopaminergic neurones: an in vitro study.Br J Pharmacol. 1996 Feb;117(3):528-532. doi: 10.1111/j.1476-5381.1996.tb15222.x. Br J Pharmacol. 1996. PMID: 8821544 Free PMC article.
-
Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain.Neurochem Res. 1998 Aug;23(8):1031-7. doi: 10.1023/a:1020799700885. Neurochem Res. 1998. PMID: 9704592
-
Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.Br J Pharmacol. 1992 Mar;105(3):569-74. doi: 10.1111/j.1476-5381.1992.tb09020.x. Br J Pharmacol. 1992. PMID: 1628144 Free PMC article.
-
Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.Naunyn Schmiedebergs Arch Pharmacol. 1991 Oct;344(4):412-8. doi: 10.1007/BF00172580. Naunyn Schmiedebergs Arch Pharmacol. 1991. PMID: 1766471
-
In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain.Naunyn Schmiedebergs Arch Pharmacol. 1995 May;351(5):475-82. doi: 10.1007/BF00171038. Naunyn Schmiedebergs Arch Pharmacol. 1995. PMID: 7543977
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources